摘要
2型糖尿病(Type 2 diabetes mellitus,T2DM)的患病率日益增加,胰岛素市场份额仍然占首位,GLP-1R激动剂市场份额不断增长,除治疗T2DM外还有减肥,心血管功能改善等多重获益。近几年在国内外治疗地位逐渐提升。本文综述了GLP-1R激动剂研发进展情况,长效及口服制剂,基础胰岛素复方制剂的开发是将来主要的研发方向。
The prevalence of type 2 diabetes mellitus (T2DM) is increasing.Insulin still dominate the main market for the treatment of type 2 diabetes mellitus.The market share of GLP-1R agonists is increasing.In addition to the treatment of T2DM,there are multiple benefits such as weight loss and cardiovascular improvement.In recent years,its status has gradually arised across the world.This paper reviews reasearch progress of GLP-1R agonistss.Development of long-acting or oral preparations,basic insulin compound preparations will be the main research and development directions in the future.
作者
周屹峰
刘平
平丽英
杨悦
傅立峰
ZHOU Yi-feng;LIU Ping;PING Li-ying;YANG Yue;FU Li-feng(Hangzhou Zhongmei Pharmaceutical Co.,Ltd.Hangzhou 310011,China)
出处
《海峡药学》
2019年第8期1-4,共4页
Strait Pharmaceutical Journal
作者简介
周屹峰,男(1983-)。学历:硕士。职称:工程师。研究方向:药物筛选及开发。E-mail:zhouyf@eastchinapharm.com.
